Drugs / DC vaccination
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07412197 | Aug 2026 → Dec 2029 expected | Lynch syndrome | Radboud University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT01885702 | Oct 2010 → Apr 2016 | colorectal cancer | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02285413 | Feb 2011 → Oct 2015 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00703105 | Oct 2008 → Jul 2021 | ovarian cancer | Loyola University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412197 ↗ |
| Modality | Vaccine | “dendritic cell vaccine” NCT00703105 ↗ |
| Route | Other | “into inguinal nodes identified by ultrasound guidance” NCT00703105 ↗ |